← FDA DRUG APPROVALS

FDA NDA · NDA208114

DEFITELIO

defibrotide sodium

Sponsor: JAZZ PHARMS INC

APPLICATION
NDA208114
TYPE
NDA
ORIGINAL APPROVAL
2016-03-30
LATEST ACTION
2016-03-30
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

DEFITELIO · ReferencePrescription
DEFIBROTIDE SODIUM 200MG/2.5ML (80MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2016-03-30Type 1 - New Molecular Entity · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →